![](https://monteverdelaw.com/wp-content/uploads/case-logo/talaris-therapeutics-inc.png)
Talaris Therapeutics Inc. (Nasdaq: TALS), relating to its proposed merger with Tourmaline Bio, Inc. Under the terms of the agreement, TALS shareholders are expected to own approximately 21.3% of the combined company.
Talaris Therapeutics Inc. (Nasdaq: TALS), relating to its proposed merger with Tourmaline Bio, Inc. Under the terms of the agreement, TALS shareholders are expected to own approximately 21.3% of the combined company.